Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, single-arm, non-randomized study designed to evaluate
PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR)
and biomarkers of cancer therapy based on Alphacait screening system in subjects with
advanced malignant tumor.